Novel Agent Offers Hope for Hereditary ATTR Polyneuropathy

The investigational antisense agent eplontersen slows disease progression and im-proves quality of life in hereditary transthyretin-mediated amyloid polyneuropathy, final data from a phase 3 trial indicate.

Related Keywords

United States ,American ,Mina Makar ,Sami Khella ,University Of Pennsylvania School Medicine ,Astrazeneca ,Ionis Pharmaceuticals Astrazeneca ,American Academy Of Neurology ,Drug Administration ,Perelman School Of Medicine ,Perelman School ,Pennsylvania School ,Penn Presbyterian Medical ,American Academy ,Global Cardiovascular ,Medscape Medical ,Amyloidosis ,Transthyretin Related Amyloidosis ,Neuropathy ,Quality Of Life ,Pol ,Ealth Related Quality Of Life ,Rqol ,Diabetic Neuropathy ,Diabetic Neuropathies ,Iabetic Nerve Damage ,Impairment ,Disability ,Geriatrics Elder Care ,Immunology ,Nerves ,Orphan Drugs ,Pennsylvania ,Rare Diseases ,